‘Walk This Way’ – a pilot of a health coaching intervention to reduce sedentary behaviour and increase low intensity exercise in people with serious mental illness: study protocol for a randomised controlled trial by unknown
STUDY PROTOCOL Open Access
‘Walk ThisWay’ – a pilot of a health coaching
intervention to reduce sedentary behaviour
and increase low intensity exercise in people
with seriousmental illness: study protocol for
a randomised controlled trial
Julie Williams1,2*, Brendon Stubbs1,2,3, Fiona Gaughran2,4,5 and Tom Craig1,2
Abstract
Background: People with serious mental illness (SMI) (psychosis, bipolar disorder and major depressive disorder)
experience a considerable risk of premature mortality because of cardiovascular disease. Recent research has
demonstrated that this population spends almost 13 h per day being sedentary. Sedentary behaviour is an
independent risk factor for cardiovascular disease and mortality. Given the potential for physical activity to improve
health and well-being in people with SMI, we developed a pilot randomised controlled trial (RCT) to evaluate a
coaching intervention aimed at reducing sedentary behaviour and increasing physical activity in people with SMI.
Our primary aim was to assess the acceptability and feasibility of the intervention. Secondary aims were to see if
the Walk This Way (WTW) intervention decreased sedentary behaviour and increased activity levels.
Methods/design: People with SMI who met any of the following criteria were recruited by two community mental
health teams in South London: (1) overweight, (2) at risk for or have diabetes, (3) smoke tobacco or (4) have a
sedentary lifestyle. Care co-coordinators (clinical case managers) identified potentially eligible participants within
their caseload, and these individuals were subsequently invited to participate. All participants’ physical activity
(self-reported and accelerometer-recorded), health status (including metabolic blood tests) and motivation to
exercise were assessed at baseline. Participants were randomised to receive treatment as usual or the WTW
intervention. WTW consisted of an educational intervention at baseline on the benefits of an active lifestyle.
Participants were then given a pedometer and received fortnightly coaching from a staff member trained in
coaching skills to help them to set daily walking targets, and they were invited to a weekly walking group.
The WTW intervention lasted 17 weeks in total.
Discussion: To our knowledge, WTW is the first RCT to investigate the impact of a health coaching intervention
targeting sedentary behaviour in people with SMI. It is hoped that if the intervention is feasible and acceptable, further
large scale study can be developed and implemented in routine care.
Trial registration: ISRCTN37724980. Registered on 4 Aug 2015.
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Background
People with serious mental illness (SMI) experience a
mortality rate two to three times higher than that of the
general population [1, 2]. This mortality gap translates
to a 10- to 20-year shortened life expectancy and appears to
be widening [2, 3]. Approximately 60 % of the excess mor-
tality observed in SMI is due to physical co-morbidities, pre-
dominantly cardiovascular diseases (CVDs) [3]. The authors
of a recent large-scale meta-analysis of 198 studies found
that 32.6 % of people with SMI have metabolic syndrome
(MetS), which is highly predictive of CVD [4]. Cardiometa-
bolic abnormalities appear to be particularly prevalent
among people in England with SMI. This is exemplified by a
recent U.K. study of 450 participants with SMI who were
using mental health services in which researchers found
that nearly all women and most men had a waist cir-
cumference exceeding the International Diabetes Feder-
ation (IDF) threshold for central obesity, with the half
of the sample being obese, one-fifth meeting the criteria
for type 2 diabetes mellitus (T2DM) and 57 % meeting
the IDF criteria for MetS [5]. Moreover, people with
schizophrenia [6], bipolar disorder [7] and major depres-
sive disorder [8] are at significantly increased risk of
T2DM. Much of the increase in CVD and MetS appears
to be related to anti-psychotic medication and unhealthy
lifestyle factors [9].
There is a plethora of literature demonstrating that
sedentary behaviour is associated with an increased risk
of T2DM, CVD and mortality in the general population
[10]. Recently, the World Health Organisation (WHO)
stated that physical inactivity is the fourth leading global
cause of avoidable mortality [11], and Public Health Eng-
land (PHE) have made calls for everybody to be active
every day [12]. Given the deleterious impact of a seden-
tary lifestyle, both the WHO and PHE now stipulate that
preventing physical inactivity is of equal importance with
encouraging smoking cessation. The authors of a recent
meta-analysis demonstrated that people with psychosis
spend almost 13 h per day being sedentary, equating to
3 h per day more than control subjects [13]. The levels of
sedentary behaviour reported in this meta-analysis are
among the highest recorded in any population. Research
regarding the harmful effects of sedentary behaviour
among people with SMI is sparse, but there is good reason
to believe that this may be particularly marked in people
with SMI. A recent study [14] demonstrated that higher
levels of sedentary behaviour is predictive of heightened
C-reactive protein (CRP) levels, a key predictor for in-
creased CVD risk.
Regarding the general population, meta-analyses of ran-
domised controlled trials (RCTs) have demonstrated that
physical activity is potentially as effective as pharmaco-
logical interventions in reducing cardiovascular mortality
[15]. Moreover, a recent meta-analysis established that
physical activity can improve anthropometric measure-
ments, psychiatric and depressive symptoms in people
with SMI [16]. However, people with SMI experience a
range of barriers to physical activity and struggle to meet
recommended target guidelines such as 150 minutes of
moderate physical activity per week. In general medicine,
there have recently been calls to place an emphasis on re-
ducing sedentary behaviour and replace this with light
physical activity for groups that frequently do not meet
recommended physical activity targets, because some
physical activity is better than none [17]. Recently, a simi-
lar call was made to consider this approach in people with
SMI [18].
In order to overcome multiple barriers, there is a need
to provide innovative, simple and enjoyable ways for people
with SMI to engage in physical activity. In the general
population, pedometer-based interventions can increase
habitual physical activity participation, decrease body mass
index (BMI), decrease systolic blood pressure and possibly
improve cholesterol [19, 20]. The authors of a recent sys-
tematic review [21] identified ten walking studies (mostly
non-RCTs) of people with schizophrenia and concluded
that there is promising evidence that walking interventions
can reduce weight and positively influence psychiatric
symptoms in people with schizophrenia. However, these
studies were all short in duration, and no high-quality
adequately powered RCT exists, nor does any study
exist in the United Kingdom. Walking is a cheap and
simple form of physical activity that may be a feasible
method to reduce sedentary behaviour and increase ha-
bitual physical activity and improve wider health out-
comes for people with SMI [21].
Given the potential opportunity to employ walking as
a strategy to reduce sedentary behaviour and improve
health among people with SMI, we developed a pilot
RCT including a pedometer-based coaching intervention
to reduce sedentary behaviour and increase habitual phys-
ical activity, called Walk This Way (WTW). Specifically,
WTW was designed to target service users with SMI who
may fall into any of the following groups: (1) overweight,
(2) at risk for or have T2DM, (3) smoke tobacco or (4)
sedentary.
Aims
The primary aim of this pilot RCT is to establish the ac-
ceptability of the WTW intervention to service users by
evaluating if participants can be recruited into the study
and if they complete the intervention. Secondary aims
are to estimate if, compared with treatment as usual
(TAU), the WTW intervention (1) reduces sedentary be-
haviour (reduce the total minutes per day of sedentary
behaviour) and (2) increases daily physical activity (light,
moderate and vigorous in minutes per day) in people
with SMI. In addition, we will consider the impact of the
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WTW versus TAU on glucose regulation, progression to




WTW is a 17-week pilot RCT programme that includes
an initial group education session, fortnightly coaching
sessions, and the provision of a pedometer and calendar
to enable participants to monitor their daily physical ac-
tivity. Participants assigned to the TAU arm will receive
brief information on the benefits of being more active
and will be given information on local walking routes of
interest. Ethical approval for the trial has been obtained
from the City Road and Hammersmith National Research
Ethics Service Committee (15/LO/1188), and the trial has
been registered in the ISRTCN Registry (ISRCTN37724980).
A flow diagram of the WTW study is shown in Fig. 1, and
the schedule of enrolment, interventions and assessments is
provided in Fig. 2.
Setting
The WTW intervention will take place in one location
within the South London and Maudsley NHS Foundation
Trust (SLaM). The team at the location has experience
Fig. 1 Walk this Way (WTW) study flow diagram
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Fig. 2 Schedule of enrolment, interventions and assessments. BMI Body mass index, International Physical Activity Questionnaire, BREQ-2 Behavioural
Regulation in Exercise Questionnaire-2, WEMWBS Warwick-Edinburgh Mental Wellbeing Scale, TUG Timed Get Up and Go Test
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with running healthy lifestyle programmes for people with
SMI.
Participants
Participants will be recruited from among community
teams in SLaM. The following eligibility criteria will be
used:
1. Diagnosis of any SMI (schizophrenia, psychosis,
bipolar disorder and major depression)
2. Meeting any one of the following criteria as
determined by a care co-ordinator:
a. Overweight
b. At risk for or have T2DM
c. In the clinician’s view, have a sedentary lifestyle
d. Smoke tobacco
3. Ability to provide informed consent
4. Ability to understand English
We aim to recruit 40 participants, 20 in the intervention
group and 20 in the control group. This number is based
on recruiting a big-enough sample to assess the feasibility
of the study and on the resources available [22].
Procedure
Researchers will work with the care co-ordinators within
each referring team to identify service users who meet
the eligibility criteria. Care co-ordinators will be asked
to identify any reasons why we should not contact people
(such as they are very unwell either physically or mentally).
All service users who meet our criteria, and where there
are no reasons not to contact them, will be sent a letter
explaining the study. This letter will be followed by a
telephone call 1 week later.
We will record the details of the service users who (1)
meet our criteria, (2) who contact us once they have re-
ceived the letter, (3) agree to meet a researcher when
contacted by us and (4) decide they do not want to meet
a researcher when contacted. This level of detail will
help us to assess the acceptability of the intervention
when described to service users. We will then record de-
tails of who takes part in the research and the rates of
drop-out from the intervention.
All service users who express an interest will be in-
vited to meet a researcher, who will explain the study
and ask if they would like to participate. They will be
given written information on the study, along with the
opportunity to ask any questions. We will give people
24 h to decide if they would like to participate. If they
are happy with the information they receive, they will be
asked to give informed consent and baseline measures
will be completed. The participant will then be asked to
wear an accelerometer for 4 days. Each participant will
be reimbursed £10 for the baseline paper measures and
£10 for wearing the accelerometer. After completion of
the baseline measures, the participants will be informed
of their allocation status.
Data collection
Primary outcome: acceptability, feasibility and recruitment
rates of the study
We will measure (1) whether it was possible to recruit
sufficient participants into the study within a particular
time frame and (2) how many people who were recruited
into the study completed the intervention.
Secondary outcomes
Sedentary behaviour and physical activity time per day
will be recorded. All participants will be required to wear
a wrist-worn GENEActiv accelerometer (GENEActiv,
Kimbolton, UK) for at least 4 days (including 1 weekend
day if possible) at baseline that will measure habitual
sedentary behaviour and walking activity each day. The
accelerometer will record how many minutes per day
each participant is sedentary and engages in light, moder-
ate and vigorous physical activities. A recording is made
of each 60-second period (called an ‘epoch’), and this is
classified as being either sedentary or light, moderate or
vigorous physical activity. The cut-off points were defined
according to metabolic equivalents (METs) of sedentary
(<1.5 METs), light (1.5–3.99 METs), moderate (4.00–6.99
METs) and vigorous (>7+ METs), based on standardised
algorithms with high sensitivity and specificity with oxy-
gen consumption [23]. For this study, we are interested in
the total minutes of sedentary behaviour per day, number
of disruptions in sedentary behaviour and total time spent
in physical activity (minutes per day in light, moderate
and vigorous activity). Specifically, we are interested in the
change in average minutes of sedentary behaviour and
physical activity before and after the WTW intervention.
We will measure if the WTW intervention group changes
pre- and post-intervention in sedentary behaviour and
physical activity and also measure if this differs from the
control group. The following outcomes will also be mea-
sured at both baseline and follow-up:
1. Anthropometric measures: We will measure BMI
according to the IDF criteria [24], including height,
weight and waist circumference.
2. Self-report sedentary behaviour and physical activity:
The International Physical Activity Questionnaire
(IPAQ) [25] will be used to capture self-reported
physical activity and sedentary behaviour. The IPAQ
has questions asking about the amount of vigorous
and moderate activity done in the last 7 days, how
often the person has walked for more than 10 minutes
in the last 7 days, and how many hours the person is
sedentary on a usual day.
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3. Motivation to engage in physical activity: The
Behavioural Regulation in Exercise Questionnaire-2
(BREQ-2) [26] is a 19-item interviewer-administered
questionnaire designed to consider an individual’s
motivation towards exercise. The BREQ-2 has been
validated in people with schizophrenia [27].
4. Blood samples: We will collect information from
blood samples taken by a phlebotomist. This
information will include fasting blood glucose,
insulin (to calculate the homeostasis model
assessment of estimated insulin resistance index),
long-term blood glucose control (as measured by
glycated haemoglobin), fasting lipids and CRP.
5. Mental well-being: We will use the Warwick-
Edinburgh Mental Wellbeing Scale [28], a 14-item
self-report measure, to assess well-being. Respondents
rate their experience regarding each statement over
the last 2 weeks. Each item is scored using a 5-point
Likert scale ranging from 1 (none of the time) to 5 (all
of the time), with the total score ranging from 14 (low
well-being) to 70.
6. Functional mobility: We will ask all participants to
complete the Timed Get Up and Go (TUG) Test
[29]. The TUG Test requires participants to stand
up from a chair, walk 3 meters, turn around, walk
back, and sit down again. The time taken is measured
in seconds, and scores represent functional mobility,
with higher scores indicating increasing mobility
difficulties. Times longer than 13.5 seconds are
predictive of falls in the general older adult
population.
We will also collect details of age, gender, ethnicity, liv-
ing arrangements, pain level, smoking status, psychiatric
diagnosis and current medications.
Randomisation
The randomisation will be done by a researcher independ-
ent of the study using the random sequence generator in
random.org. The researchers will not know which arm the
participant has been consigned to before the baseline as-
sessment. Participants will be told if they have been rando-
mised to either the intervention and control group after
the baseline assessment.
Walk This Way intervention
Initial group education session
Participants assigned to the WTW intervention will at-
tend a baseline educational group session which will in-
clude a minimum of five and a maximum of ten people,
depending on the rate of recruitment, and is amended
from the Walk, Address sensations, Learn about exercise,
Cue exercise behaviour for persons with schizophrenia
spectrum disorders (‘WALC-S’) programme [30, 31],
which is a motivational intervention based upon the
self-efficacy theory. The aim of the sessions will be to
introduce the basics of the benefits of walking for exer-
cise and why exercise is beneficial, as well as to give in-
formation, support and motivation to help participants
to independently walk more in their daily routines. In
the group sessions, we will also introduce the concept
of sedentary behaviour and the harms and strategies to
sit less and move more, including disrupting prolonged
periods of sitting. At the educational session, researchers
will have information on the participants’ habitual levels
of physical activity obtained from baseline data collection.
The group session will also include goal setting, in which
participants will be encouraged to set their own daily
walking targets to increase their habitual levels of walking.
All participants will be given a pedometer to self-monitor
how far they walk throughout the intervention on a daily
basis. Specifically, participants will be given a Yamax Digi-
Walker CW-700 pedometer (Yamasa Tokei Keiki Co.,
Ltd., Tokyo, Japan), which is the criterion pedometer with
optimal accuracy. It provides direct step-count feedback
to participants, and participants will be encouraged to
self-monitor their daily activity levels and record them on
an individualised calendar.
The principles of coaching will also be presented during
the education session, and the participants will be intro-
duced to their ‘coach’. Finally, all participants will go on a
walk to ensure they are able to operate their pedometers.
Continuing support and coaching
Participants will meet with an assigned worker (i.e., their
coach) every 2 weeks. The participant and coach will re-
view the participant’s walking calendar and address any
barriers to and facilitators of engaging in physical activity
and reducing sedentary behaviour. The participant’s daily
walking target (number of steps per day) will be reviewed
and amended as required by setting SMART (Specific,
Measurable, Attainable, Realistic and Timely) goals with
the patient. The brief meetings (lasting 20–30 minutes)
every 2 weeks will provide an opportunity for the worker
to provide motivational support to assist the participant to
reach his or her daily step goals. If the worker identifies
barriers such as inappropriate footwear, then the worker
will be given funds to purchase appropriate footwear for
the participant. The staff doing the coaching will have
training in goal attainment and coaching skills because
this has been found to increase motivation and adherence
[32]. Coaching is being used more often in mental health
services, and a recent study of coaching to reduce obesity
in people with SMI had encouraging results [33]. Coach-
ing sessions will be audiotaped to assess fidelity, and the
coaches will have regular supervision sessions with a
coaching specialist.
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In addition, the worker will arrange for all members
who attended the group educational session to continue
to meet every week for a regular group walk. This will
provide an element of social support but will remain op-
tional for the participants.
Control condition
Participants in the control group will complete baseline
measures, and then they will receive written information
on the benefits of increasing activity levels. This advice
will be given in accordance with NHS Foundation Trust
policy on physical health.
Follow-up assessment
The follow-up assessment will be undertaken at the end
of the intervention. At follow-up, all measures will be re-
peated (apart from sociodemographic information). Each
participant will be paid £10 for the paper measures and
£10 for wearing the accelerometer. These assessments
will be done by a research worker who is blind to alloca-
tion status. We will attempt to follow all participants, in-
cluding those who discontinue the intervention early.
Process evaluation
In addition to the outcome assessment, we will also
undertake a qualitative process evaluation to find out (1)
how participants experienced the intervention, if there
are any parts of the intervention that need to be chan-
ged, and what factors influenced people in completing/
not completing the intervention; and (2) how the staff
doing the coaching intervention experienced this. We
will also use this process evaluation to ask service users
about the issues they have regarding their physical health
and what support they would like with this.
Data management
Each participant will be given an identification number.
All information collected will be kept confidential; all
identifiable data will be kept in a locked cabinet; and
forms with identifiable data will be kept separate from
the outcome data. The outcome data will be collected
on paper forms, and the data will then be transferred to
an IBM SPSS database (IBM, Armonk, NY, USA). Data
quality will be enforced by having range checks, valid
values and data double-entry. We will collect all infor-
mation on instances of adverse events, including hospi-
talisation for either mental or physical problems, as well
as any mental health relapse or home treatment team in-
volvement or accident and emergency visit. Any changes
to the protocol will be reported to the research ethics
committee. The final dataset will be accessed by the
principal investigator and the research team. The proto-
col, the anonymised participant level dataset and any
statistical codes used will be made available on request.
Analysis
For the primary aim and to evaluate feasibility, we will
calculate the percentage of people approached who partici-
pate in the intervention and the percentage who complete
the intervention. We will use the process evaluation to
understand how the intervention was experienced by par-
ticipants and any changes that they think would improve
the intervention.
To evaluate the effectiveness of the intervention, we
will investigate changes in pre- and post-test scores for
the secondary outcome measure (total minutes of seden-
tary behaviour per day and total minutes of physical ac-
tivity) of the WTW participants. We will also investigate
changes in the pre- and post-test scores for the other
outcome measures. We will compare the mean changes
in sedentary behaviour and physical activity (light, moder-
ate and vigorous) in the WTW group versus the control
group.
Discussion
This pilot aims to evaluate the feasibility and acceptabil-
ity of an intervention to support people with SMI using
secondary mental health services to increase their level
of activity. If WTW proves to be acceptable, we plan to
undertake a larger RCT to assess the effectiveness of
such an intervention.
The physical health of people with SMI has become a
priority for both primary and secondary services in recent
years to address the identified mortality gap. Improving
the physical health of people with SMI will require a
multifaceted approach that includes the identification of
physical health risks to ensure effective treatment is given
and interventions are initiated to reduce physical health
risks. This is happening at a time when there is a growing
awareness of the risks of sedentary behaviour in the gen-
eral population which is leading to approaches to reduce
sedentary behaviour in all.
National Institute for Health and Care Excellence
guidelines for people with schizophrenia recommend
that interventions be offered to support people with SMI
to be more active [34], but there are few evidence-based
interventions which clinicians can offer. An intervention
that is found to be acceptable to people with SMI would
be a welcome addition to the field.
Trial status
The trial is ongoing and no longer recruiting.
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